{
    "clinical_study": {
        "@rank": "152906", 
        "arm_group": [
            {
                "arm_group_label": "Sugar Pill", 
                "arm_group_type": "Placebo Comparator", 
                "description": "Identical placebo pills twice daily for 8 weeks Placebo pills manufactured to mimic appearance of intervention drug n-acetylcysteine and prescribed with identical frequency and duration."
            }, 
            {
                "arm_group_label": "N-Acetylcysteine", 
                "arm_group_type": "Active Comparator", 
                "description": "1800 mg twice daily for 8 weeks"
            }
        ], 
        "brief_summary": {
            "textblock": "N-acetylcysteine (NAC) is described as having mucolytic and antioxidant properties. It is\n      widely prescribed for patients with chronic obstructive lung disease (COPD), particularly\n      for those who have accompanying symptoms of chronic cough and sputum production. Compared to\n      placebo, high-dose NAC will improve Saint George Respiratory Questionnaire scores in\n      patients with COPD and chronic bronchitis."
        }, 
        "brief_title": "N-Acetylcysteine for Patients With COPD and Chronic Bronchitis", 
        "condition": [
            "COPD", 
            "Chronic Bronchitis"
        ], 
        "condition_browse": {
            "mesh_term": [
                "Bronchitis", 
                "Acute Disease", 
                "Bronchitis, Chronic", 
                "Pulmonary Disease, Chronic Obstructive", 
                "Lung Diseases, Obstructive"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Capability to provide written informed consent\n\n          -  Age \u2265 40 years and \u2264 85 years\n\n          -  FEV1/FVC ratio (post bronchodilator) < 70%\n\n          -  FEV1 (post bronchodilator) < 65%\n\n          -  Presence of chronic cough and sputum production defined as the following:\n\n          -  Presence of chronic cough and sputum will be defined by responses to the    first two\n             questions on the SGRQ. Subjects who respond positively to both question 1 (cough) and\n             question 2 (sputum) on the SGRQ as either \"several days per week\" or \"almost every\n             day\" will be eligible\n\n          -  Current or former smoker with lifetime cigarette consumption of at least 10\n             pack-years\n\n          -  Negative serum pregnancy test at the baseline visit if patient is a pre-menopausal\n             female (menopause defined as absence of a menstrual cycle in the last 12 months)\n\n          -  Must be fluent in speaking the English language\n\n        Exclusion Criteria:\n\n          -  Not fully recovered for at least 30 days from a COPD exacerbation characterized by\n             typical symptoms and treated with antibiotics or prednisone\n\n          -  Known allergy or sensitivity to NAC or albuterol\n\n          -  Any patient with unstable cardiac disease\n\n          -  Any patient with a documented history of uncompensated congestive heart failure in\n             the last 2 years\n\n          -  Clinical diagnosis of asthma, bronchiectasis, cystic fibrosis, or severe alpha-1\n             antitrypsin deficiency\n\n          -  Active lung cancer or history of lung cancer if it has been less than 2 years since\n             lung resection or other treatment. If history of lung cancer, must have no evidence\n             of recurrence in the 2 years preceding the baseline visit.\n\n          -  Undergoing active treatment for malignancy except for hormonal therapy (i.e. prostate\n             cancer, breast cancer) or non-metastatic skin cancer and are not symptomatic\n\n          -  Chronic kidney disease with an estimated GFR of < 30 ml/min. GFR will be estimated\n             using the Modification of Diet in Renal Disease (MDRD) formula\n\n          -  History of cirrhosis with evidence of portal hypertension (ascites, chronic edema)\n\n          -  Participation in a pulmonary rehabilitation program or completion within past 6 weeks\n\n          -  Prisoners or institutionalized patients\n\n          -  Participation in another study involving an investigational product within 30 days of\n             the baseline visit\n\n          -  Pregnant or breast-feeding patients.\n\n          -  Use of guaifenesin in the last 30 days\n\n          -  Currently on long acting nitrates for angina or heart failure\n\n          -  Abnormalities in screening blood work defined as:\n\n          -  WBC < 3.0 or > 15.0 K/cmm\n\n          -  Hemoglobin < 9.0 or > 17.0 gm/dl\n\n          -  Platelets < 75 or > 400 K/cmm\n\n          -  ALT > 3 times the upper limit of normal\n\n          -  INR > 1.5 unless on warfarin therapy\n\n          -  Any concomitant condition that might endanger the patient through participation in\n             the study or interfere with study procedures, as assessed by the investigator"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "85 Years", 
            "minimum_age": "40 Years"
        }, 
        "enrollment": {
            "#text": "40", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "November 29, 2012", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01739790", 
            "org_study_id": "1210M21542"
        }, 
        "intervention": [
            {
                "arm_group_label": "N-Acetylcysteine", 
                "description": "1800 mg twice daily for 8 weeks", 
                "intervention_name": "N-Acetylcysteine", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "Sugar Pill", 
                "intervention_name": "Identical Placebo manufactured to mimic appearance of intervention drug with identical frequency and duration", 
                "intervention_type": "Drug"
            }
        ], 
        "intervention_browse": {
            "mesh_term": [
                "Acetylcysteine", 
                "N-monoacetylcystine"
            ]
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "keyword": [
            "COPD", 
            "Chronic Bronchitis", 
            "N-acetylcysteine"
        ], 
        "lastchanged_date": "December 5, 2013", 
        "location": {
            "contact": {
                "email": "rreilkof@umn.edu", 
                "last_name": "Ronald A Reilkoff, MD", 
                "phone": "612-624-0999"
            }, 
            "facility": {
                "address": {
                    "city": "Minneapolis", 
                    "country": "United States", 
                    "state": "Minnesota", 
                    "zip": "55455"
                }, 
                "name": "University of Minnesota"
            }, 
            "status": "Not yet recruiting"
        }, 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "2", 
        "official_title": "Effects of High-Dose N-Acetylcysteine on Respiratory Health Status in Patients With Chronic Obstructive Pulmonary Disease (COPD) and Chronic Bronchitis: A Randomized, Placebo-Controlled Trial-3", 
        "overall_contact": {
            "email": "rreilkof@umn.edu", 
            "last_name": "Ronald A Reilkoff, MD", 
            "phone": "612-624-0999"
        }, 
        "overall_contact_backup": {
            "email": "edinx004@umn.edu", 
            "last_name": "Cheryl Stibbe, RN", 
            "phone": "612-624-0999"
        }, 
        "overall_status": "Not yet recruiting", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration", 
            "has_dmc": "Yes"
        }, 
        "phase": "N/A", 
        "primary_completion_date": {
            "#text": "January 2014", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "measure": "Changes in the Saint George's Respiratory Questionnaire", 
            "safety_issue": "No", 
            "time_frame": "Baseline to 8 weeks"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01739790"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "source": "University of Minnesota - Clinical and Translational Science Institute", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "University of Minnesota - Clinical and Translational Science Institute", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "January 2013", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "December 2013"
    }
}